Profits and first quarter sales of Swiss drugmaker Novartis have met their 2020 targets following sales at its generics unit continuing through the coronavirus lockdown without disruptions its business. Novartis’ core net income rose to $3.55 billion, up from $2.8… Read More ›
The Swiss drugmaker’s board is seeing some reshuffles, including on at its diagnostics business, which had been held by Michael Heuer on an interim basis. On Tuesday, Swiss drugmaker Roche announced changes to its board and executive leadership. Longtime director… Read More ›
manageria.biz 